84 Percent higher risk of cardiac-related death among males 18-39 years with MRNA vaccine: Analysis sparks fear against Pfizer, Moderna vaccine

Published On 2022-10-11 13:00 GMT   |   Update On 2022-12-14 11:50 GMT

Creating a scare among the patients world-wide taking the mRNA-based COVID vaccine, a recent advisory has been released by the Florida Department of Health in the US recommending against the COVID-19 mRNA vaccines for males ages 18-39 years oldThis came after a recent analysis done by the Florida Department of Health (Department) revealed that there is an 84% increase in the relative incidence...

Login or Register to read the full article

Creating a scare among the patients world-wide taking the mRNA-based COVID vaccine, a recent advisory has been released by the Florida Department of Health in the US recommending against the COVID-19 mRNA vaccines for males ages 18-39 years old

This came after a recent analysis done by the Florida Department of Health (Department) revealed that there is an 84% increase in the relative incidence of cardiac-related death among males 18-39 years old within 28 days following mRNA vaccination, whereas non-mRNA vaccines were not found to have these increased risks among any population.

For more details, check out the link given below:

84 Percent Higher Risk Of Cardiac-Related Death Among Males 18-39 Years With MRNA Vaccine: Analysis Sparks Fear Against Pfizer, Moderna Vaccine


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News